newsfilter
← Latest News
GlobeNewswire·

Elutia Secures $15 Million Loan Financing from Avenue Capital Group to Fund NXT-41x Launch in $1.5 Billion Plastic and Reconstructive Surgery Market

ELUT
  • Elutia Inc. secured a $15 million growth capital financing agreement with Avenue Capital Group.
  • $10 million was funded at closing on August 13, 2026, with a second $5 million tranche unlocked upon FDA 510(k) clearance of NXT-41x.
  • The financing preserves shareholder value by funding commercialization without an equity offering.
  • NXT-41x is a next-generation antibiotic-eluting biomatrix targeting 15–20% post-operative infection rates in complex plastic & reconstructive surgeries.
  • The U.S. market opportunity for NXT-41x is estimated at $1.5 billion.
  • FDA clearance for NXT-41x is anticipated in the first half of 2027.
  • The deal strengthens Elutia's balance sheet & extends its operational runway.